Location History:
- Menlo Park, CA (US) (2005 - 2007)
- Ironwood, NC (US) (2007)
- Ironwood, MI (US) (2009 - 2013)
Company Filing History:
6 out of 2,010 
2 out of 1,168 Years Active: 2005-2013
Title: **Zishan A. Haroon: A Trailblazer in Cancer Biomarkers and Therapeutics**
Introduction
Zishan A. Haroon, an innovative inventor based in Ironwood, MI, has made significant contributions to the field of cancer research. With a remarkable portfolio of six patents, his work focuses on the utilization of cytokine receptors as biomarkers and therapeutic targets in human cancer. His pioneering inventions are poised to enhance the understanding and treatment of cancer, providing hope to many.
Latest Patents
One of Zishan A. Haroon's latest patents details the "Use of cytokine receptors as biomarkers and therapeutic targets in human cancer." This patent involves nucleic acids encoding erythropoietin receptor isoforms, along with methods for detecting these isoforms and strategies for screening and treating cancer. Additionally, his innovative approach emphasizes the importance of these receptors in understanding tumor biology and potentially guiding therapeutic interventions.
Career Highlights
Zishan has worked at prestigious institutions that foster research and innovation, including Duke University and Yeda Research and Development Company. His experiences in these organizations have equipped him with a rich understanding of the intersection between research and practical application, allowing him to develop impactful solutions in the field of oncology.
Collaborations
Throughout his career, Zishan A. Haroon has collaborated with esteemed colleagues such as Murat O. Arcasoy and Mark W. Dewhirst. Their synergistic efforts have likely contributed to advancing cancer research and enriching the scientific community's knowledge regarding cytokine receptors and their roles in cancer therapy.
Conclusion
Zishan A. Haroon stands out as a prominent inventor within the realm of cancer research. His dedication to developing new therapeutic targets and biomarkers reflects a broader commitment to improving cancer diagnostics and treatment protocols. With ongoing innovations, Zishan's contributions may continue to shape the future of oncology, offering the potential for groundbreaking advancements in the fight against cancer.